Actinium Pharma Offers Prelim. Results From Phase 2 Trial For Actimab-A At ASH: '69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 µCi/kg/fraction as a single agent'